Fibrocell Science Inc.

NASDAQ: FCSCHealthcare / Drugs - Generic / USA
1.97-0.0200-1.01%Vol 20 0861Y Perf -37.17%
Jun 24th, 2019 16:00
BID1.93 ASK1.97
Open1.99 Previous Close1.99
Pre-Market- After-Trading-
 - -%  - -%
Target Price
16.00 
Analyst Rating
Strong Buy 1.00
Potencial %
712.18 
Finscreener Ranking
★★★★+ —    -
Insiders Trans % 3/6/12M
-/-/100 
Value Ranking
★★★ —    -
Insiders Value % 3/6/12M
-/-/100 
Growth Ranking
★★★ —    -
Insiders Shares Cnt. % 3/6/12M
-/-/100 
Income Ranking
 —    -
Market Cap (mil)19 
Earnings Rating
Neutral
Price Range Ratio 52wk %
27.23 
Earnings Date
8th Aug 2019

Today's Price Range

1.941.99

52wk Range

1.453.36

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Month
1.02%
3 Months
-20.40%
6 Months
32.67%
1 Year
-37.17%
3 Years
-86.04%
5 Years
-96.80%

Name / TickerPriceChg.Chg.%
FCSC1.97-0.0200-1.01
AAPL198.58-0.2000-0.10
GOOG1 115.52-6.3600-0.57
MSFT137.780.81000.59
XOM76.95-0.7400-0.95
WFC46.27-0.6200-1.32
JNJ143.060.97000.68
FB192.601.46000.76
GE10.28-0.2000-1.91
JPM108.66-0.7800-0.71
Earnings HistoryEstimateReportedSurprise %
Q01 2019-0.33-0.40-21.21
Q04 2018--0.14-
Q03 2018-0.83-0.2866.27
Q02 2018-0.42-0.49-16.67
Q01 2018-0.85-0.5535.29
Q04 2017-1.15-3.25-182.61
Q03 2017-2.05-1.7017.07
Q02 2017-1.60-1.553.12
Earnings Per EndEstimateRevision %Trend
6/2019 QR-0.38--
9/2019 QR-0.28--
12/2019 FY-1.31--
12/2020 FY-1.13--
Next Report Date8th Aug 2019
Estimated EPS Next Report-0.38
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume20 086
Shares Outstanding (in ths.)9 758
Trades Count37
Dollar Volume34 350
Avg. Volume588 522
Avg. Weekly Volume43 617
Avg. Monthly Volume224 054
Avg. Quarterly Volume831 823
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Fibrocell Science Inc.

Fibrocell Science Inc is active in the healthcare sector. It is an autologous cell and gene therapy company focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue, and joints. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa and its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma.

CEO: John Maslowski

Teplephone: +1 484 713-6000

Address: 405 Eagleview Boulevard, Exton 19341, PA, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

82%18%

Bearish Bullish

56%44%

Bearish Bullish

63%37%

News